相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre-Marie Morice et al.
LANCET HAEMATOLOGY (2021)
Myelodysplastic syndrome and acute myeloid leukemia as side effect of PARP inhibitors.
Samip R. Master et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton et al.
NATURE GENETICS (2020)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Pedram Razavi et al.
NATURE MEDICINE (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era
Lindsay M. Morton et al.
JAMA ONCOLOGY (2019)
Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States
Rahul Shenolikar et al.
GYNECOLOGIC ONCOLOGY (2018)
Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
Jacob Korach et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis et al.
LANCET ONCOLOGY (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Koichi Takahashi et al.
LANCET ONCOLOGY (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs et al.
CELL STEM CELL (2017)
Therapy-related myeloid neoplasms: when genetics and environment collide
Megan E. McNerney et al.
NATURE REVIEWS CANCER (2017)
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M. Swisher et al.
JAMA ONCOLOGY (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Chi Young Ok et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
分享论文
